U.S. FTC sues Endo Pharma,Others for blocking Generic Versions Of some branded drugs
Friday, April 01, 2016
FTC Sues Endo Pharmaceuticals Inc. And Others For Illegally Blocking Lower-Cost Generic Versions Of The Branded Drugs Opana Er And Lidoderm.
Suit alleges Endo entered into pay-for-delay patent settlements with Impax and Watson to delay generic entry; endo partner settles.
Complaint alleges that Endo paid Impax Laboratories, inc. And Watson Laboratories, inc. To eliminate the risk of competition for opana er and lidoderm.
Complaint also names Allergan plc, the parent company of Watson, and Endo International plc, the parent company of endo pharmaceuticals inc.
Source : reuters.com
